Roche's Breast Cancer Drug Perjeta Receives Green Light From EU

Today, Roche declared that the European Union gave a positive recommendation for the use of Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and docetaxel in patients with HER2-positive metastatic or location specific recurrent breast cancer that cannot be removed with surgery. This announcement verifies a suggestion for people with this certain type of cancer who have not yet received anti-HER2 therapy or chemotherapy for their cancer. The positive recommendation was based on overall survival and progression-free survival data from the phase III CLEOPATRA study...

Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/CrV3hxi4yuE/254104.php

medical rehab